Peppermint
drugOn this page
Also known as Ae-peppermintB1449Brandy mint flowering topLamb mint flowering topMentha crispa flowering topMentha dumetorum flowering topMentha piperitaMentha piperita flowering topMentha x piperitaMentha x piperita flowering topPeppermint flowering topPeppermint powderPeppermint wholefresh
Summary
Peppermint (CHEMBL2108553) is a phase-3 clinical-stage unknown; indicated across 1 condition including severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 1 condition
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108553 |
| Name | Peppermint |
| Type | Unknown |
| Max phase | 3 |
Also known as: Ae-peppermint, B1449, Brandy mint flowering top, Lamb mint flowering top, Mentha crispa flowering top, Mentha dumetorum flowering top, Mentha piperita, Mentha piperita flowering top, Mentha x piperita, Mentha x piperita flowering top, Peppermint, Peppermint flowering top
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05799053 | PHASE3 | COMPLETED | Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study |
| NCT07493434 | Not specified | ENROLLING_BY_INVITATION | Evaluation of Pain Thresholds in Migraine Patients After Inhalation of Essential Oils: a Randomized Clinical Trial |
| NCT02163369 | Not specified | UNKNOWN | The Use of Aromatherapy for Symptom Management |
| NCT03436173 | Not specified | COMPLETED | OxSYPan: Oxford Study With Young People on Antidepressants |
| NCT03475836 | Not specified | COMPLETED | Cognitive Effects of Mint Essential Oil |
| NCT04474951 | Not specified | UNKNOWN | Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies |
| NCT04866407 | Not specified | TERMINATED | Topical Eucalyptus Globulus and Mentha x Piperita on Muscle Soreness in Older Adults and the Elderly |
| NCT04874298 | Not specified | UNKNOWN | The Effect of Ginger and Peppermint on Postoperative Nausea and Vomiting in Patients After Thyroid Surgery |
| NCT05071833 | Not specified | COMPLETED | Effects of Peppermint Oil in Cardiometabolic Outcomes |
| NCT06095726 | Not specified | COMPLETED | Peppermint Inhalation Versus Swedish Massage on Chemotherapy Induced-Nausea and Vomiting in Children With Leukemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: severe acute respiratory syndrome